{"id":"NCT05032157","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-12-01","primaryCompletion":"2023-12-18","completion":"2024-01-05","firstPosted":"2021-09-02","resultsPosted":"2024-11-01","lastUpdate":"2025-04-08"},"enrollment":455,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Spontaneous Urticaria"],"interventions":[{"type":"DRUG","name":"LOU064 (blinded)","otherNames":["remibrutinib"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"LOU064 (open-label)","otherNames":["remibrutinib"]}],"arms":[{"label":"LOU064 25mg b.i.d.","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to establish the efficacy, safety, and tolerability of Remibrutinib 25 mg b.i.d. in adult patients suffering from chronic spontaneous urticaria (CSU) inadequately controlled by second generation H1-antihistamines (H1-AHs) in comparison to placebo.","primaryOutcome":{"measure":"Mean Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12 (Scenario 1 With UAS7 as Primary Efficacy Endpoint)","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"LOU064 25 mg b.i.d.","deltaMin":-19.41,"sd":0.702},{"arm":"Placebo","deltaMin":-11.73,"sd":0.948}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":9},"locations":{"siteCount":122,"countries":["United States","Austria","Brazil","Canada","China","Denmark","Germany","India","Malaysia","Poland","Russia","Slovakia","South Africa","Switzerland","Taiwan","Thailand","United Kingdom","Vietnam"]},"refs":{"pmids":["40043237"],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=2430"]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":297},"commonTop":["COVID-19","Nasopharyngitis","Upper respiratory tract infection","Headache","Suspected COVID-19"]}}